China Pharmaceutical Innovation and Research Development Association (herein after referred to as PhIRDA) and Hong Kong Exchanges and Clearing Limited (herein after referred to as HKEX) signed Memorandum of Understanding on the HKEX Biotech Summit 2018 held on March 22. Both sides decided to build a closer collaboration through holding regular meetings among the senior administrative staff and seminars for research projects; continue to exchange ideas on further improving the regulations to be listed in Hong Kong and related administrations; support and encourage biotech companies with all efforts to be listed in Hong Kong. Song Ruilin, Executive President of PhIRDA and Charles LI, Chief Executive of HKEX, witnessed the signing ceremony of Memorandum of Understanding on cooperation between PhIRDA and HKEX, which was represented by Feng Lan, Secretary-General of PhIRDA and Mao Zhirong, Managing Director and Head of HKEX Mainland Development. Chung Kong CHOW, Chairman of HKEX Group and other representatives from pharmaceutical investment institutions and innovation companies participated in the ceremony.
Representatives from PhIRDA and HKEX signed the MOU
Co-hosted by China Pharmaceutical Innovation and Research Development Association (PhIRDA) and Suzhou Industrial Park Administrative Office (SIPAC) and co-organized by Chinese American Hematologist and Oncologist Network (CAHON), SINO-U.S.